A1 Refereed original research article in a scientific journal
Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate
Authors: Kristina Stuopelyte, Rasa Sabaliauskaite, Arnas Bakavicius, Benedikta S. Haflidadóttir, Tapio Visakorpi, Riina-Minna Väänänen, Chintan Patel, Daniel C. Danila, Hans Lilja, Juozas R. Lazutka, Albertas Ulys, Feliksas Jankevicius, Sonata Jarmalaite
Publisher: NLM (Medline)
Publication year: 2020
Journal: Journal of Urology
Journal name in source: The Journal of urology
Volume: 204
Issue: 1
First page : 71
Last page: 78
Number of pages: 7
ISSN: 1527-3792
eISSN: 1527-3792
DOI: https://doi.org/10.1097/JU.0000000000000803
Self-archived copy’s web address: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301408/
PURPOSE: Reliable molecular diagnostic tools are still unavailable for making informed treatment decisions and monitoring the response in patients with castration resistant prostate cancer. We evaluated the significance of whole blood circulating androgen receptor transcripts of full length (AR-FL) and splice variants (AR-V1, AR-V3 and AR-V7) as biomarkers of abiraterone acetate treatment resistance in patients with castration resistant prostate cancer.
MATERIALS AND METHODS: After retrospective analysis in 112 prostate specimens AR-FL, AR-V1, AR-V3 and AR-V7 were evaluated in 185 serial blood samples, prospectively collected from 102 patients with castration resistant prostate cancer before and during abiraterone acetate therapy via reverse transcription quantitative polymerase chain reaction.
RESULTS: AR-FL was present in all samples while AR-V1, AR-V3, AR-V7 and at least 1 of them was detected in 17%, 55%, 65% and 81% of castration resistant prostate cancer blood samples, respectively. The highest amount of AR-V1 was found in blood of patients whose response time was short and medium in comparison to extended. Patients with a higher level of AR-FL and/or AR-V1 had the shortest progression-free survival and overall survival (p <0.0001).
CONCLUSIONS: Blood circulating AR-FL or AR-V1 can serve as blood based biomarkers for identification of the primary resistance to abiraterone acetate and the tool to monitor de novo resistance development during abiraterone acetate treatment.
